Speakers

James Armitage, Michael Deininger, B Mark Evers, Roger Fleischman, Roger Herzig, Gerhard Hildebrandt, Maxwell Krem, Gregory Monohan, Reinhold Munker, Reshma Ramlal, Paul Richardson, Hayder Saeed, Alvin Schmaier

James Armitage, MD

The Joe Shapiro Professor of Medicine
Division of Oncology and Hematology
College of Medicine, University of Nebraska Medical Center
The Fred and Pamela Buffett Cancer Center
Omaha, Nebraska

Dr. James O. Armitage graduated from the University of Nebraska Medical Center in 1973 where he completed his internship and residency in internal medicine in 1975. In 1977 he completed a fellowship in hematology-oncology at the University of Iowa Hospitals and Clinics, Iowa City, Iowa. Dr. Armitage was in private practice from 1977-79, and in 1979 he returned to the University of Iowa as an Assistant Professor of Medicine, where he developed and was director of the Bone Marrow Transplantation Program. In 1982 he returned to Nebraska as as Associate Professor of Medicine and was promoted in 1987 to Professor of Medicine. He has served as Vice Chairman of the Department of Medicine (1982-90), Chief of the Division of Oncology/Hematology (1986-89), Chairman of the Department of Internal Medicine (1990-99), Dean, College of Medicine (2000-03), and presently holds the position of the Joe Shapiro Professor of Medicine. He is a member of several professional organizations as well as an editor of the ASCO publications ASCO Post and Journal of Oncology Practice. He is a Fellow of the American College of Physicians, the Royal College of Physicians and ASCO. He has served as President of ASCO (1996-97) and President of ASBMT (2000-01). He has authored or co-authored over 500 articles, over 100 book chapters, and is the editor/co-editor of 27 books.

Back to top

Michael Deininger, MD

Chief-Division of Hematology and Hematologic Malignancies
M.M. Wintrobe Professor of Medicine
Senior Director for Transdisciplinary Research
University of Utah, Huntsman Cancer Institute
Salt Lake City, Utah

Michael Deininger is Professor and Chief of Hematology and Hematologic Malignancies in the Department of Internal Medicine and the Huntsman Cancer Institute (HCI) at the University of Utah. He is an HCI investigator and member of the Experimental Therapeutics program. He has extensive experience treating patients with blood cancers, including chronic myeloid leukemia (CML) and myeloproliferative neoplasms, a group of blood cancers related to leukemia.

Dr. Deininger received his MD from the University of Würzburg Medical School, Germany, in 1990. Throughout his studies he was funded by the prestigious German Scholarship Foundation. He subsequently trained in Internal Medicine and Hematology/Oncology. In 1995 he obtained a grant to enroll in the PhD program at Imperial College, London. His thesis work focused on signal transduction and the potential use of imatinib (Gleevec) as molecularly targeted therapy for CML. After returning to Germany he completed a fellowship in stem cell transplantation at the University of Leipzig Medical Center. In 2002 he was recruited to the Division of Hematology and Medical Oncology at Oregon Health & Science University as an Assistant Professor. In 2007 he was promoted to the rank of Associate Professor and became the Head of the Hematologic Malignancies Section at OHSU. In August 2010 Dr. Deininger became the M.M. Wintrobe Professor of Medicine at the University of Utah and was appointed Chief of the Division of Hematology and Hematologic Malignancies. He was also appointed Senior Director for Transdisciplinary Research at Huntsman Cancer Institute.

Dr. Deininger’s scientific focus is leukemia, specifically myeloproliferative neoplasms (MPN) including CML, chronic myelomonocytic leukemia (CMML) and myelofibrosis (MF). As a clinician-scientist with a translational research focus Dr. Deininger is heading an extramurally funded research laboratory that is dedicated to the study of signaling pathways, drug resistance and new molecular therapies in leukemia. Dr. Deininger’s work describing the selective effects of imatinib on CML cells provided the rationale for clinical trials that led to the approval of Gleevec as the first molecularly-based therapy for leukemia. Current work in his lab is focused on understanding the role of the bone marrow microenvironment in leukemia drug resistance, discovering novel therapeutic targets and developing more specific signal transduction inhibitors. Dr. Deininger’s work encompasses more than 200 articles in the peer-reviewed literature, including journals like Cancer Cell, Blood, Journal of Clinical Investigation and the New England Journal of Medicine. He has co-authored more than 10 book chapters, with contributions in leading textbooks such as deVita’s Principles of Oncology. He is a regular speaker at major international scientific meetings, such as the American Society of Hematology and the European Hematology Association and a peer reviewer for journals like Nature Genetics and Cancer Cell. His honors include the Alexandra Kefalides Prize for Leukemia Research, membership on the Editorial Board of Blood (the leading journal in Hematology) and Thompson Reuters Highly Cited Researcher award in 2014 and 2015. Dr. Deininger serves as the vice-Chair for NCCN CML panel and is a member of the NCCN MPN panel. As of 2016 he is a standing member of the Developmental Therapeutics Study Section, Center for Scientific Review.

Back to top

B Mark Evers, MD, FACS

Markey Cancer Foundation Endowed Chair Director of the Lucille P. Markey Cancer Center
Professor and Vice-chair for Research
Department of Surgery
Physician-in-Chief of the Oncology Service Line
UK HealthCare
Markey Cancer Center
College of Medicine
University of Kentucky
Lexington, Kentucky

At the University of Kentucky, Dr. Evers is the Markey Cancer Foundation Endowed Chair, Director of the Lucille P. Markey Cancer Center, and Professor and Vice-chair for Research in the Department of Surgery. He also serves as the Physician-in-chief of the Oncology Service Line for UK HealthCare.

Dr. Evers graduated summa cum laude (Phi Beta Kappa) from the University of Tennessee in 1979 and summa cum laude (Alpha Omega Alpha) from the University of Tennessee Health Science Center in 1983. He completed his surgical training at the University of Louisville and then performed a research fellowship at the University of Texas Medical Branch (UTMB) in Galveston from 1988-1990. Prior to joining UK in 2009, Dr. Evers was Professor and Robertson-Poth Distinguished Chair in General Surgery and the Director of the UTMB Sealy Center for Cancer Cell Biology.

Dr. Evers’ research has been continuously funded by the NIH for more than 20 years, including an NIH MERIT Award, multiple R01s, and training grants. He has authored more than 400 peer-reviewed publications, book chapters, and reviews. Throughout his career, he has received more than 30 awards, including the prestigious Flance-Karl Award from the American Surgical Association, and held numerous leadership positions in national and international organizations. These include the Society for Surgical Oncology, American College of Surgeons, and the American Gastroenterological Association. He is an elected member of the American Society of Clinical Investigation and the Association of American Physicians. Dr. Evers has held the positions of President of the Society of University Surgeons, Secretary and President the Southern Surgical Association, and Senior Director of the American Board of Surgery. He is currently Treasurer of the American Surgical Association. Dr. Evers serves on the editorial boards of three journals, is a past member of two NIH study sections, and acts as Associate Editor of the Sabiston Textbook of Surgery. In 2015, he was honored with an “Outstanding Alumnus” award from the University of Tennessee College of Medicine. Dr. Evers has been listed in “Best Doctors in America” since 2004. At the state level, Dr. Evers is a member of the Kentucky Lung Cancer Research Program Governance Board and a member of the Kentucky Colon Cancer Screening Program Advisory Committee. In 2013, he was elected to the Mid-South Board of Directors for the American Cancer Society.

Dr. Evers led efforts to achieve National Cancer Institute (NCI) designation for the University of Kentucky Markey Cancer Center in 2013. The Markey Cancer Center is one of only 69 cancer centers designated by the NCI and the only one in Kentucky. Dr. Evers is currently leading preparation of the 2017 renewal application to the NCI.

Back to top

Roger Fleischman, MD

Associate Professor
Division of Hematology/BMT
University of Kentucky College of Medicine
Lexington, Kentucky

Roger A. Fleischman received his undergraduate and medical degrees from Harvard College and Harvard Medical School in Cambridge, Mass. After a medical residency at the Brigham and Women’s Hospital in Boston, he completed a fellowship in Hematology and Oncology at the University of Pennsylvania School of Medicine in Philadelphia. During the fellowship, he also engaged in basic research in the biology of blood and bone marrow stem cells at the Institute for Cancer Research at the Fox Chase Cancer Center in Philadelphia.

Dr. Fleischman accepted his first faculty position in Hematology/Oncology at the University of Texas Southwestern Medical School, Dallas in 1983 and served as a practicing clinician at Parkland Memorial Hospital in Dallas as well as a clinical and basic researcher into the molecular causes of bone marrow and stem cell disorders.

In 1993, Dr. Fleischman left Texas for the University of Kentucky and was appointed an Associate Professor of Internal Medicine in the Hematology/Oncology Division. As part of his duties at UK HealthCare, he also serves as Chief of the Hematology/Oncology Section at the Lexington VA Hospital. At UK HealthCare, he see patients primarily with lymphoma, leukemia, and other bone marrow disorders.

Dr. Fleischman has published many research papers and abstracts and my research has been presented at numerous meetings both national and international. He was also recently recognized by the Hematology/Oncology fellows for outstanding teaching. He received 2015 designation as a Distinguished Emeritus Member by the American Society of Hematology for “exemplary service and efforts in the advancement of the field of hematology”. He is married to Dr. Elizabeth Piercy, an Infectious Disease specialist in private practice in Lexington, and they have two daughters.

Back to top

Roger Herzig, MD

Professor/Director of Blood and Marrow Transplantation
Division of Hematology/BMT
University of Kentucky
Lexington, Kentucky

My name is Roger Herzig; I received my medical degree from Case Western Reserve University, School of Medicine, Cleveland. I completed fellowships in Hematology at Case Western Reserve University, Cleveland and the National Cancer Institute, Bethesda, Md.

Back to top

Gerhard Hildebrandt, MD

Professor, Medicine
University of Kentucky College of Medicine
Division Chief, Hematology and Blood & Marrow Transplantation
UK HealthCare
Lexington, Kentucky

Dr. Hildebrandt earned a medical degree from the Johannes Gutenberg University of Mainz Medical School, Germany. Upon completing his doctoral research thesis, he was awarded the "doctor medicinae" with magna cum laude. He completed a residency in Internal Medicine and a Hematology and Oncology fellowship at the University of Regensburg, Germany, and became Bone Marrow Transplant and Hematologic Malignancies Attending at the University of Regensburg. In 2009, he was awarded the "Habilitation", the highest academic qualification a scholar can achieve by own pursuit in Germany.

After moving to the United States, he was a faculty member at the Louisiana State University in Shreveport and at the University of Utah. He was the director of the bone marrow transplant program at LSUHSC Shreveport and director of the Utah Blood and Marrow Transplant program at the Huntsman Cancer Institute/University of Utah before moving to Kentucky.

He is a member of ASH, ASCO, ASBMT, AACR, the author of more than forty articles, books, and book chapters and is strongly involved in clinical trials.

Dr. Hildebrandt focuses on patients with cancers of the blood and lymph system, patients before and after blood or marrow stem cell transplantation, and on patients suffering from acute and chronic graft versus host disease.

Back to top

Maxwell Krem, MD,PhD

Assistant Professor
Division of Hematology/BMT
University of Kentucky College of Medicine
Lexington, Kentucky

Back to top

Gregory Monohan, MD

Associate Professor
Department of Hematology and Blood & Marrow Transplantation
Fellowship Director, Hematology/Medical Oncology
Markey Cancer Center
University of Kentucky
Lexington, Kentucky

Dr. Monohan received his MD from the University of Kentucky College of Medicine. He served his residency with the Indiana University School of Medicine and a fellowship with the University of Kentucky. Dr. Monohan's clinical interests include benign and malignant hematology, blood and marrow transplantation and multiple myeloma. He is certified with the American Board of Internal Medicine, Hematology and Medical Oncology.

Back to top

Reinhold Munker, MD

Professor
Division of Hematology/BMT
University of Kentucky College of Medicine
Lexington, Kentucky

Reinhold Munker is Professor of Medicine at the University of Kentucky in Lexington where he works in the Division of Hematology and Blood & Marrow Transplantation. His basic science interests are broad (from proliferation of leukemic cells to microRNAs to autoantibodies in cancer). His clinical research spans late effects of cancer treatment to epidemiology and rare types of leukemia. He treats patients with benign and malignant blood disorders and is involved in immunotherapy and stem cell transplantation. Dr. Munker’s research has resulted in more than 140 publications and 19 books and chapters of books.

Back to top

Reshma Ramlal, MD

Assistant Professor
Division of Hematology/BMT
University of Kentucky
Lexington, Kentucky

Dr. Reshma Ramlal is hematologist in Lexington, KY and is affiliated with University of Kentucky Albert B. Chandler Hospital. She received her medical degree from the University of the West Indies , Faculty of Medical Science, Port of Spain and received her residency training at the University of Florida Health Science Center in Jacksonville, FL. She received her hematology/oncology fellowship training at St. Louis University Hospital and stem cell transplantation training at the University of Texas, MD Anderson Cancer Center in Houston, TX. She has been in practice for 8 years.

Back to top

Paul Richardson, MD

R.J. Corman Professor
Dana-Farber/Harvard Cancer Center
Boston, Massachusetts

Dr. Paul Richardson received his medical degree from the Medical College of St. Bartholomew's Hospital, University of London, and was chief resident at the Royal Marsden Hospital, London. After a clinical fellowship at Baystate Medical Center of Tufts University School of Medicine, he joined Dana-Farber Cancer Institute where he is a Professor of Medicine at the Harvard Medical School. In addition, Dr. Richardson serves as Clinical Program Leader and Director of Clinical Research of the Jerome Lipper Multiple Myeloma Center and has led several novel, biologically-derived translational efforts in multiple myeloma.

Dr. Richardson is board certified in hematology, internal medicine, and medical oncology. He holds numerous advisory board positions and is a member of dozens of professional organizations. In addition, he has published hundreds of original papers, reviews, chapters, and monographs in many leading peer-reviewed publications including The New England Journal of Medicine, Blood, Journal of Clinical Oncology, Lancet Oncology, Lancet Hematology, Clinical Cancer Research, Bone Marrow Transplantation, JAMA Oncology, and the British Journal of Hematology. Dr. Richardson has led the study and clinical development of numerous novel drugs in the treatment of multiple myeloma which have contributed to improvement in outcome for patients.

Back to top

Hayder Saeed, MD

Assistant Professor
Hematology and Medical Oncology
University of Kentucky
Lexington Kentucky

Dr. Hayder Saeed is a medical oncologist in Lexington, Kentucky and is affiliated with University of Kentucky Albert B. Chandler Hospital. He received his medical degree from University of Baghdad College of Medicine and has been in practice between 6-10 years.

Back to top

Alvin Schmaier, MD

Robert W. Kellermeyer Professor of Hematology and Oncology
University Hospitals Cleveland Medical Center
Case Western Reserve University
Cleveland, Ohio

Back to top